Program Description & Educational Objectives
In this activity, an expert in multiple sclerosis responds to three questions about patient cases submitted in a recent survey of US neurologists. The discussion focuses on how the most current data translate into clinical practice.
Upon completion of this activity, participants should be better able to:
- Discuss the efficacy, safety, and tolerability of appropriate treatment options for both newly diagnosed patients with multiple sclerosis and those who have failed prior therapy
- Describe treatment strategies to help manage spasticity associated with multiple sclerosis
This activity has been designed to meet the educational needs of neurologists and other healthcare professionals who care for patients with multiple sclerosis.
Requirements for Successful Completion
In order to receive credit, participants must view the activity and complete the post-test and evaluation form. There are no pre-requisites and there is no fee to participate in this activity or to receive CME credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.
Release and Expiration Dates: March 15, 2013 - March 14, 2014
Time to Complete: 15 minutes
Faculty & Disclosure / Conflict of Interest Policy
In accordance with ACCME requirements, Penn State College of Medicine has a conflict of interest policy that requires faculty to disclose relevant financial relationships related to the content of their presentations/materials. Any potential conflicts are resolved so that presentations are evidence-based and scientifically balanced.
Aaron E. Miller, MD
Professor of Neurology
Corinne Goldsmith Dickinson Center for Multiple Sclerosis
Mount Sinai School of Medicine
New York, New York
Aaron E. Miller, MD, has a financial interest/relationship or affiliation in the form of:
Consultant for Acorda Therapeutics, Inc.; Biogen Idec; EMD Serono, Inc. (Merck Serono); GlaxoSmithKline; Novartis Corporation; Nuron Biotech; Ono Pharmaceutical Group; sanofi-aventis; and Teva Pharmaceuticals.
Grant/Research Support from Acorda Therapeutics, Inc.; Biogen Idec; Genentech, Inc.; Hoffmann-La Roche Inc.; Novartis Corporation; and sanofi-aventis.
Answers in CME, Inc.
Annette Wiggins currently has no financial interests/relationships or affiliations in relation to this activity.
Answers in CME staff who may potentially review content for this activity have disclosed no relevant financial relationships.
Penn State College of Medicine staff and faculty involved in the development and review of this activity have disclosed no relevant financial relationships.
Sponsorship, Credit & Support
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Penn State College of Medicine and Answers in CME. Penn State College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.
The Penn State College of Medicine designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Information about CME credit for this activity is available by contacting Penn State at 717-531-6483 or ContinuingEd@hmc.psu.edu. Reference course # G5234-13-T.
This CME activity is jointly sponsored by Penn State College of Medicine and Answers in CME.
This activity is supported by an educational grant from
Additional support provided by Penn State College of Medicine and Answers in CME.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.
No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports.
Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings.